新辅助内分泌治疗：谁获益最大？

Neoadjuvant Endocrine Therapy: Who Benefits Most?

作者信息

Grossman Julie, Ma Cynthia, Aft Rebecca

机构信息

Department of Medicine, Washington University, 660 South Euclid Avenue, St Louis, MO 63110, USA.

Department of Surgery, Washington University, 660 South Euclid Avenue, St Louis, MO 63110, USA.

出版信息

Surg Oncol Clin N Am. 2018 Jan;27(1):121-140. doi: 10.1016/j.soc.2017.07.008.

DOI:10.1016/j.soc.2017.07.008

PMID:29132556

Abstract

Neoadjuvant endocrine therapy (NET) can be effective at downstaging patients with estrogen receptor-positive tumors and identifying those tumors that are endocrine sensitive and resistant. The optimal prognostic markers for stratification are under investigation. Use of NET will allow the identification of patients with estrogen receptor-positive tumors who might benefit from additional treatment and allow better understanding of endocrine resistance.

摘要

新辅助内分泌治疗（NET）对于降低雌激素受体阳性肿瘤患者的分期以及识别那些对内分泌敏感和耐药的肿瘤可能是有效的。用于分层的最佳预后标志物正在研究中。NET的应用将有助于识别可能从额外治疗中获益的雌激素受体阳性肿瘤患者，并有助于更好地理解内分泌耐药性。